In this study, urinary NGAL was an independent risk factor for nonresponse to volume expansion therapy in patients with cirrhosis and AKI, and the cutoff value for urinary NGAL was 90.75 ng/ml. The gene discussed is LCN2; the disease is Cirrhosis.